About this trial
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness
Disqualifiers
age<18 years
unable to read, understand and sign the written informed consent
unable to perform visual field test
advanced glaucoma with C/D>0.7
Trial population
glaucoma patients referring to glaucoma clinic of IRCCS-Fondazione GB Bietti and University of Rome Tor Vergata.
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect
central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.
Secondary outcomes
the agreement between 24-2c HFA and G1 Octopus in detecting central visual field defect
central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.